Table 1b. UCDA use in PBC patients between 2000 and 2015.
| Year (no. of cases) | 2000 (n=158) | 2001 (n=178) | 2002 (n=209) | 2003 (n=226) | 2004 (n=252) | 2005 (n=269) | 2006 (n=288) | 2007 (n=317) |
|---|---|---|---|---|---|---|---|---|
| No. of patients receiving UDCA | 108 (68.4%) | 131 (73.6%) | 152 (72.7%) | 160 (70.8%) | 187 (74.2%) | 205 (76.2%) | 210 (72.9%) | 225 (71.0%) |
| Year (no. of cases) | 2008 (n=358) | 2009 (n=421) | 2010 (n=501) | 2011 (n=530) | 2012 (n=560) | 2013 (n=584) | 2014 (n=625) | 2015 (n=656) |
| No. of patients receiving UDCA | 267 (74.6%) | 331 (78.6%) | 404 (80.6%) | 436 (82.3%) | 463 (82.7%) | 475 (81.3%) | 531 (85.0%) | 564 (86.0%) |
PBC, primary biliary cholangitis; UCDA, ursodeoxycholic acid.